• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

PRIORIX FDA approval expands supply of MMR vaccines

Video

In a video for Contemporary Pediatrics®, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses an expansion of vaccine access likely to come with the FDA approval of the PRIORIX vaccine.

Tina Tan, MD, FAAP, FIDSA, FPIDS, editor-in-chief, Contemporary Pediatrics®; attending, division of infectious disease; medical director, international patient and destination services program at Ann & Robert H. Lurie Children’s Hospital of Chicago; and professor of pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, discussed the recent US Food and Drug Administration (FDA) approval of the PRIORIX (GSK plc) vaccine for measles, mumps, and rubella prevention. In a video, Tan highlighted the likely increase of vaccine availability due to the approval, which adds another manufacturer to the market and decreases the likelihood of shortages. Additionally, she noted that the PRIORIX vaccine can be used as a second dose to another, previously used MMR vaccine.

Related Videos
Importance of maternal influenza vaccination recommendations
Samantha Olson, MPH
Related Content
© 2024 MJH Life Sciences

All rights reserved.